Hims & Hers Health, Inc.

Neutral

Last updated: 05/08/2025, 08:54:41

Executive Summary

Hims & Hers Health, Inc., a telehealth company founded in 2017, has positioned itself as a leader in the digital health space by offering a range of health and wellness products and services. The company has experienced significant revenue growth, reporting $1.48 billion for FY2024, up from $872 million in FY2023, alongside a positive EBITDA of $78.99 million. However, recent developments, including a revenue miss in Q2 2025 and the initiation of class action lawsuits, have raised concerns about its growth trajectory and investor confidence.

While the macroeconomic environment appears favorable for Hims & Hers, with low inflation and stable interest rates potentially supporting consumer spending, the company faces substantial risks. These include high valuation ratios that suggest potential overvaluation, ongoing legal challenges, and intense competition in the telehealth sector. As Hims & Hers navigates these complexities, its ability to sustain growth and maintain a competitive edge will be critical for its long-term success.

The Hims & Hers Health, Inc. Story

Founded in 2017 and headquartered in San Francisco, California, Hims & Hers Health, Inc. is a telehealth company that provides a range of health and wellness products and services, focusing on areas such as sexual health, hair loss, skincare, and mental health.

Initially launched as a men’s wellness brand, Hims quickly gained traction by offering discreet access to prescription medications and health consultations online. The company expanded its offerings to include Hers, targeting women’s health issues, and marked significant milestones such as going public via a SPAC merger in early 2021. Hims & Hers has pivoted to emphasize a broader telehealth model, integrating personalized care and a subscription-based service that allows customers to receive ongoing treatments conveniently at home. This innovative approach has positioned the company as a leader in the digital health space, catering to the evolving needs of consumers seeking accessible healthcare solutions.

Macro Industry Position

Hims & Hers Health, Inc. operates in the telehealth and wellness industry, providing a range of health and wellness products and services, including prescription medications, skincare, and mental health support. This sector is part of the broader healthcare industry, which includes global giants like Teladoc Health, UnitedHealth Group, and CVS Health.

Specifically, Hims & Hers focuses on telemedicine services, prescription drugs for conditions such as erectile dysfunction and hair loss, as well as skincare products. Key competitors in this niche include Roman and Keeps, which also offer similar telehealth services and products aimed at men's health and wellness.

In the US, the current inflation rate stands at 2.7% year-over-year, which is relatively low and can positively influence consumer spending on health and wellness products. A stable inflation rate may encourage more individuals to seek out telehealth services, as they feel more secure in their financial situations. The US 10-year yield is at 4.23%, down 14 basis points, indicating a slight easing in borrowing costs, which could make it more attractive for Hims & Hers to invest in growth initiatives or expand their service offerings.

Looking at the broader economic indicators, the Fed-funds rate remains unchanged at 4.33%, suggesting that the Federal Reserve is maintaining its current monetary policy stance. This stability can foster a favorable environment for businesses like Hims & Hers, as it reduces uncertainty in the financial markets. Meanwhile, inflation rates in the Euro-area and the UK are also relatively low, which could signal a global trend that supports consumer health spending, although these regions are not the primary focus for Hims & Hers.

Bottom line: The backdrop is favorable for Hims & Hers Health, Inc., as low inflation and stable interest rates create a conducive environment for growth in the telehealth and wellness sector.

Recent Developments

Hims & Hers Health, Inc. (HIMS) released its second-quarter 2025 results on August 4, 2025. The company reported a GAAP revenue of $544.8 million, which represented a 73% increase year over year. However, this figure fell short of the consensus GAAP estimate of $551.7 million by 1.2%. The earnings per share (EPS) for the quarter was $0.17, which missed the Zacks Consensus Estimate of $0.18 per share. This was an improvement from the earnings of $0.06 per share reported in the same quarter the previous year.

Following the earnings report, Hims & Hers stock experienced a significant decline. Shares fell by 10% in after-hours trading on August 4, 2025, primarily due to the revenue miss. The stock's performance raised concerns among investors regarding the company's growth trajectory, particularly in the context of its third-quarter forecast, which also did not meet Wall Street's expectations.

On the same day, Hims & Hers faced legal challenges as two law firms announced class action lawsuits against the company. Robbins Geller Rudman & Dowd LLP stated that investors who suffered substantial losses between April 29, 2025, and June 23, 2025, had until August 25, 2025, to seek appointment as lead plaintiff in the class action lawsuit. Similarly, Bleichmar Fonti & Auld LLP also filed a lawsuit against Hims & Hers and certain senior executives for potential violations of federal securities laws.

The combination of a revenue miss, a drop in stock price, and the initiation of class action lawsuits indicates a challenging period for Hims & Hers. Investors may need to closely monitor the company's performance and legal developments as they could impact future stock performance and investor sentiment. The upcoming third-quarter results and any further legal proceedings will be critical for assessing the company's stability and growth potential.

Financial Deep-Dive

Financial Health Summary

Hims & Hers Health, Inc. reported a remarkable revenue of $1.48 billion for FY2024, a substantial increase from $872 million in FY2023. The company also achieved a positive EBITDA of $78.99 million, a significant turnaround from the previous year's loss of $19.94 million. In the latest quarter, Hims & Hers generated a revenue of $586.01 million, with an EBITDA of $66.17 million and an operating cash flow of $251.08 million, indicating strong operational performance.

Despite these impressive growth figures, several financial metrics warrant caution. The price-to-earnings ratio stands at 85.54, suggesting that Hims & Hers may be overvalued relative to its earnings. Additionally, the company has a high price-to-sales ratio of 7.65 and a price-to-book ratio of 25.6, which could indicate inflated market expectations. Furthermore, the limited disclosure of metrics may have hindered a comprehensive analysis of the company's financial health.

The single biggest financial risk that investors must track is the company's high valuation ratios, particularly the price-to-earnings and price-to-sales ratios. These metrics suggest that Hims & Hers may be vulnerable to market corrections if growth expectations are not met. Additionally, the ongoing legal challenges could further impact investor sentiment and financial stability.

Verdict: Hims & Hers Health, Inc. has demonstrated strong revenue growth and improved EBITDA, but its high valuation ratios and potential legal risks present significant concerns for investors. Caution is advised as the company navigates these challenges.

Risks and Concerns

Hims & Hers Health, Inc. faces significant risks stemming from its recent financial performance, particularly highlighted by a revenue miss in the second quarter of 2025. The company reported GAAP revenue of $544.8 million, which fell short of the consensus estimate of $551.7 million by 1.2%. This shortfall not only led to a 10% decline in stock price during after-hours trading but also raised concerns among investors regarding the company's growth trajectory, especially as it prepares for its third-quarter forecast, which has also not met Wall Street's expectations.

Additionally, the company is grappling with legal challenges, as evidenced by the initiation of class action lawsuits from two law firms. These lawsuits, which target potential violations of federal securities laws, could result in substantial financial liabilities and further erode investor confidence. The timeline for these legal proceedings, particularly the deadline for investors to seek lead plaintiff status by August 25, 2025, adds an element of uncertainty that could impact the company's stock performance and overall stability.

Furthermore, Hims & Hers' high valuation ratios pose a significant risk. With a price-to-earnings ratio of 85.54 and a price-to-sales ratio of 7.65, the company may be overvalued relative to its earnings and sales figures. Such inflated market expectations could make Hims & Hers vulnerable to market corrections if it fails to meet growth targets. As the competitive landscape in the telehealth sector continues to evolve, the company must innovate and adapt to changing consumer needs to avoid losing market share and experiencing declining revenues.

Outlook

As Hims & Hers Health, Inc. navigates the evolving landscape of telehealth and wellness, its future prospects appear to be shaped by a combination of innovative service offerings, expanding market presence, and the ongoing challenges of competition and regulatory scrutiny. The company's commitment to addressing a broad spectrum of health and wellness needs positions it well to capture a diverse customer base, while its focus on enhancing user experience through technology-driven solutions could foster greater customer loyalty and retention. However, the potential for increased competition in the telehealth space and the complexities of regulatory compliance may pose hurdles that require strategic agility and adaptability.

Looking ahead, Hims & Hers has the opportunity to leverage its brand recognition and customer trust to further penetrate existing markets and explore new verticals. The growing acceptance of telehealth services, accelerated by recent global health trends, presents a favorable environment for expansion. Additionally, partnerships with healthcare providers and integration of advanced technologies could enhance service delivery and broaden the company's appeal. Nevertheless, the ability to sustain growth will depend on effectively managing operational challenges and maintaining a competitive edge in a rapidly changing industry landscape. As such, the company's strategic decisions in the coming months will be critical in determining its trajectory and long-term success.

Red & Green Flags

This section distills all of the report’s positives (green flags), negatives (red flags) and open questions (unknowns) into one place.

Action Checklist

Below are the next research steps a retail investor should consider based on this report.

Disclaimer

This Company Report is based on publicly available information and original research, and is provided for informational purposes only. It does not constitute financial, investment, or legal advice, nor an offer or solicitation to buy or sell any security. Readers should conduct their own due diligence and consult qualified advisors before making any investment decisions. Company performance can change rapidly and past results are not a guarantee of future outcomes. The author and publisher accept no responsibility for any actions taken based on this report.